<DOC>
	<DOC>NCT01728025</DOC>
	<brief_summary>The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.</brief_summary>
	<brief_title>Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Long QT patients with genetic confirmation of carrierstatus for the D1790G mutation in the SCN5A gene Corrected QT interval &gt; 460 msec Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Long QT syndrome</keyword>
	<keyword>Ranolazine</keyword>
</DOC>